Therapy Areas: Central Nervous System
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
17 January 2025 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) and pharmaceutical company Jiangsu Aosaikang Pharmaceutical Co Ltd (ASK Pharm) (SZ:002755) announced on Thursday...
Anavex reports positive long-term data for blarcamesine in early Alzheimer's disease
13 January 2025 - Clinical-stage biopharmaceutical company Anavex Life Sciences Corp (Nasdaq: AVXL) on Monday reported data showing that over three years of continuous treatment with blarcamesine demo...
Johnson & Johnson agrees acquisition of Intra-Cellular Therapies Inc
13 January 2025 - Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Monday that it has entered into a definitive agreement to acquire Intra-Cellular Therapies Inc (Na...
Neuraxpharm acquires Provigil and Nuvigil to expand CNS portfolio
7 January 2025 - European specialty pharmaceutical company focused on central nervous system (CNS) disorders Neuraxpharm Group announced on Tuesday that it has acquired Provigil (modafinil) and Nuvigi...
Nuvation Bio secures NMPA approval for taletrectinib in China
6 January 2025 - Biopharmaceutical company Nuvation Bio Inc (NYSE: NUVB) announced on Monday that it has received approval from China's National Medical Products Administration (NMPA) for taletre...
JCR Pharmaceuticals and Modalis Therapeutics advance to next phase of joint gene therapy research
6 January 2025 - Pharmaceuticals company JCR Pharmaceuticals Co, Ltd (TOKYO: 4552) and Modalis Therapeutics Corporation (TOKYO: 4883), a research and development company, on Monday announced the succe...